Annals of Surgery · 2012 · 41 citations · 37 references
MedicineMolecular GeneticsPathologyCancer GeneticsMolecular OncologyMolecular PathologyCancer Molecular DiagnosticsMutation AnalysisThyroid CancerThyroid CytologyThyroid DisordersThyroid Nodule EvaluationMutationNeedle Aspiration BiopsyNondiagnostic Thyroid CytologyPapillary Thyroid Carcinoma CytologyPreoperative DiagnosisThyroid Fine-needle Aspiration CytologyThyroid Nodule CytologyThyroid Nodule Cytopathology
In Brief Objectives: To evaluate prospectively the usefulness of the routine determination of BRAFT1799A mutation on thyroid fine-needle aspiration biopsy (FNAB) to detect cytopathology false negative papillary thyroid carcinomas (PTC) and, therefore, as a tool to improve the sensitivity of the preoperative cytopathological diagnosis of PTC in thyroid nodules. Background: FNAB is the most reliable diagnostic test to discriminate between malignant and benign thyroid nodules, but nondiagnostic results remain a clinical management dilemma. BRAFT1799A mutation is the most prevalent genetic alteration in thyroid cancers and is specific for PTC, characteristics that make it the most potentially helpful genetic tool to improve the diagnostic accuracy of FNAB. Methods: An exhaustive recruitment of all patients subjected to thyroid FNAB in our institution during 4 years was performed. BRAFT1799A mutation was determined on thyroid FNAB specimens by PCR and restriction fragment length polymorphism, plus direct sequencing in positive samples. Results: BRAFT1799A mutation on FNAB detected 47.2% (17/36) of PTC cases. It confirmed preoperatively 45.5% (5/11) of the PTC cases in the indeterminate category and decreased the rate of cytopathology false-negatives in 33.3% (6/18), improving the combined (BRAFT1799A mutation + cytopathological analysis) sensitivity of the detection of PTC on FNAB in 16.7%. Conclusions: BRAFT1799A mutation improves the diagnosis of PTC on FNAB, mainly because of the detection of cytopathology false-negatives, and it can be helpful in the routine analysis of thyroid nodules, especially in clinical settings with moderate sensitivity to detect PTC on FNAB. BRAFT1799A mutation was analyzed in 966 thyroid cytologies (814 patients). The BRAFT1799A mutation discriminated preoperatively 45.5% (5/11) of papillary thyroid carcinomas (PTC) cytologically diagnosed as indeterminate and decreased per se the rate of cytopathology false-negative PTCs in 33.3% (6/18), increasing diagnostic sensitivity from 50.0% to 66.7%.
37
Mutations of the BRAF gene in human cancer
Helen Davies, Graham R. Bignell, Charles Cox et al. · Nature · 2002 · 10.7K citations
Scott A. Hundahl, Irvin D. Fleming, Amy M. Fremgen et al. · Cancer · 1998 · 1.8K citations · Full text
Medicine, Oncology, Cancer Control +16
BRAF Mutation in Papillary Thyroid Carcinoma
Yoram Cohen, Mingzhao Xing, Elizabeth Mambo et al. · JNCI Journal of the National Cancer Institute · 2003 · 924 citations · Full text
Zubair Baloch, Virginia A. LiVolsi, Syl L. et al. · Diagnostic Cytopathology · 2008 · 885 citations